safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-44Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESИнгибиторы натрий-глюкозного котранспортера 2: риск кетоацидозаInhibitors of sodium-glucose cotransporter 2: risk of ketoacidosisБукатинаТ. М.BukatinaT. M.noemail@neicon.ruКазаковА. С.KazakovA. S.noemail@neicon.ruВельцН. Ю.VeltsN. Yu.noemail@neicon.ruДармостуковаМ. А.DarmostukovaM. A.noemail@neicon.ruКолесниковаЕ. Ю.KolesnikovaE. Yu.noemail@neicon.ruАляутдинР. Н.AlyautdinR. N.noemail@neicon.ruРомановБ. К.RomanovB. K.noemail@neicon.ruНаучный центр экспертизы средств медицинского примененияРоссияScientific Centre for Expert Evaluation of Medicinal ProductsRussian Federation201620022018023339Copyright © Букатина Т.М., Казаков А.С., Вельц Н.Ю., Дармостукова М.А., Колесникова Е.Ю., Аляутдин Р.Н., Романов Б.К., 20182018Букатина Т.М., Казаков А.С., Вельц Н.Ю., Дармостукова М.А., Колесникова Е.Ю., Аляутдин Р.Н., Романов Б.К.Bukatina T.M., Kazakov A.S., Velts N.Y., Darmostukova M.A., Kolesnikova E.Y., Alyautdin R.N., Romanov B.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/44

Ингибиторы SGLT2 образуют новый класс гипогликемических препаратов. Несмотря на благоприятные фармакокинетические свойства, на данный момент существует неоднозначное мнение относительно их безопасности. Это связано с увеличением количества сообщений в FDA и EMA о риске развития серьезной нежелательной реакции - кетоацидоза, который не указан в инструкции в числе возможных побочных эффектов. На фоне терапии ингибиторами SGLT2 кетацидоз у пациентов с сахарным диабетом 2 типа развивается на фоне умеренного повышения уровня глюкозы (200 мг/дл/11,1 ммоль/л). В статье рассматриваются сообщения о кетоацидозе, обусловленном угнетением SGLT2 и описываются предположительные внутренние патофизиологические механизмы, связанные с этим классом лекарственных средств.

SGLT2 inhibitors form a new class of hypoglycemic drugs. Despite of the pharmacodynamic profile, at the moment the opinion about their safety is controversial. This is due to increased number of reports given by FDA and EMA on the risk of serious adverse reactions - ketoacidosis, which is not specified in the instruction as a possible adverse effects. Ketatsidosis in patients with type 2 diabetes on therapy with SGLT2 inhibitors was appeared at moderately elevated glucose levels (200 mg/dL/11.1 mmol/L). The article deals with reports of ketoacidosis, caused by inhibition of SGLT2 and describes the alleged internal pathophysiological mechanisms associated with its development.

ингибиторы SGLT2кетоацидозсахарный диабет 2 типамеханизмыinhibitors of SGLT2ketoacidosistype 2 diabetesmechanismsReferencesJung ChH, Jang JE, et al. A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes Metab J. 2014; 38(4): 261-273.Jung ChH, Jang JE, et al. A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes Metab J. 2014; 38(4): 261–273.Ушкалова ЕА. Новый класс антидиабетических препаратов - ингибиторы натрий-глюкозных котранспортеров. Фарматека. 2013;16:33-36.Ushkalova EA. A new class of antidiabetic drugs—ingibitors of sodium-glucose cotransporter. Farmateka. 2013; 16: 33–36.Городецкий ВВ, Городецкая ГИ, Ших ВЕ и соавт. Возможности медикаментозной модуляции изоферментов цитохрома Р-450, метаболизирующих препараты сульфонилмочевины. Ведомости «Научного центра экспертизы средств медицинского применения». 2014;4:22-26.Gorodetskiy VV, Gorodetskaya GI, Shikh EV et al. Opportunities for pharmacological modulation cytochrome P450 isoenzymes metabolizing sulfonylurea derivatives. Scientific Centre for Evaluation of Medicinal Products Bulletin.2014; 4: 22–26.Нурбекова АА. Канаглифлозин - новый препарат для лечения сахарного диабета. Medicine. 2015;12:53-62.Nurbekova AA. Kanagliflozin—a new drug for the treatment of diabetes. Medicine. 2015; 12: 53–62.Strojek KH, Yoon KH, Hruba V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab, 2011; 13: 928-38.Strojek KH, Yoon KH, Hruba V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24- week, double-blind, placebo- controlled trial. Diabetes Obes Metab, 2011; 13: 928–38.Matthews DR, Fulcher G, Perkovic V et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes [abstract 764]. Diabetologia. 2012; 55: 314.Matthews DR, Fulcher G, Perkovic V et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added- on to insulin therapy +/– oral agents in type 2 diabetes [abstract 764]. Diabetologia. 2012; 55: 314.Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010; 5:133-41.Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010; 5:133–41.Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev, 1994. 74:993-1026.Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev, 1994. 74:993–1026.Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev, 2011; 91:733-94.Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev, 2011; 91:733–94.Santer R, Kinner M et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol, 2003; 14:2873-82.Santer R, Kinner M et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol, 2003; 14:2873–82.Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010; 5:133-41.Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010; 5:133–41.Канаглифлозин, дапаглифлозин, эмпаглифлозин. ГРЛС. Инструкции по применению. [Электронный ресурс]. URL: http://www.grls.rosminzdrav.ru/grls.aspx/State Register of Medicinal Products. Canagliflozin, dapagliflozin, empagliflozin. Instructions for use. [Electronic resource]: URL: http://www.grls.rosminzdrav.ru/grls.aspx/Lamos EM, Younk LM, Davis SM. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol, 2013; 9(6): 763-75.Lamos EM, Younk LM, Davis SM. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol, 2013; 9(6): 763–75.Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes, 2012;5:313-27.Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes, 2012;5:313–27.Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab, 2015;100(8): 2849-52.Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab, 2015;100(8): 2849–52.Surya PR, Wilding JP. SGLT2 inhibition and ketoacidosis - should we be concerned?, Br J Diabetes Vasc Dis. 2015;15:155-158.Surya PR, Wilding JP. SGLT2 inhibition and ketoacidosis — should we be concerned?, Br J Diabetes Vasc Dis. 2015;15:155–158.Sodium glucose co-transporter 2 (SGLT2) inhibitors. [Электронный ресурс]. URL:http://www.who.int/medicines/publications/newsletter/en/#.Sodium glucose co-transporter 2 (SGLT2) inhibitors. [Electronic source]. URL: http://www.who.int/medicines/publications/newsletter/en/FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections (03. 12.2015 г.). [Электронный ресурс]. URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm.FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections (03.12.2015 ã.). [Electronic source]. URL:http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm.

The authors declare that there are no conflicts of interest present.